Interleukin‐1 Trap Rilonacept Improved Health‐Related Quality of Life and Sleep in Patients With Recurrent Pericarditis: Results From the Phase 3 Clinical Trial RHAPSODY

Interleukin‐1 Trap Rilonacept Improved Health‐Related Quality of Life and Sleep in Patients With Recurrent Pericarditis: Results From the Phase 3 Clinical Trial RHAPSODY

Background Recurrent pericarditis is characterized by painful flares and inflammation, which negatively impact health‐related quality of life. RHAPSODY (rilonacept inhibition of interleukin‐1 alpha and beta for recurrent pericarditis: a pivotal symptomatology and outcomes study) evaluated the effica...

Full description

Bibliographic Details
Main Authors: Antonio Brucato, Michelle Z. Lim‐Watson, Allan Klein, Massimo Imazio, David Cella, Paul Cremer, Martin M. LeWinter, Sushil Allen Luis, David Lin, Dor Lotan, Massimo Pancrazi, Lucia Trotta, Brittany Klooster, Leighann Litcher‐Kelly, Liangxing Zou, Matt Magestro, Alistair Wheeler, John F. Paolini
Format: Article
Language:English
Published: Wiley 2022-10-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
inflammation
interleukin‐1
patient‐reported outcome measures
pericarditis
quality of life
rilonacept
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.121.023252

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.121.023252

Similar Items